# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Rao Veena						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Predictive Oncology Inc.</u> [ POAI ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
													_	X Direc	ctor	tor		wner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 07/03/2023									Offic below	er (give title w)		Other (specify below)		
2915 COMMERS DRIVE, SUITE 900					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
														X Forn	n filed by Or	ne Re	porting Pers	son	
(Street) EAGAN	M	MN 55121												Forn	Form filed by More than One Reporting Person				
(City) (State) (Zip) Rule 10b5-1(c) Transaction Indic											lica	ation	_						
Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See																			
		Table	l - Noi	n-Deriva	tive S	ecur	rities Acq	uired,	Disp	osed of	f, o	r Ben	efici	ally Ow	ned				
1. Title of Security (Instr. 3) 2. Transac   Date (Month/Date)					Execution Date,		Transaction Disposed Code (Instr. and 5)		ties Acquired (# 1 Of (D) (Instr. 3			4 Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount		(A) or (D)	Price		ted action(s) 3 and 4)					
Common Stock 07/03/2					2023	023		A		2,675		Α	\$ <mark>0</mark>	) 3	3,974		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execut if any			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		f g	8. Price of Derivative Security (Instr. 5) Beneficia Owned Following Reported Transacti (Instr. 4)		У	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

### Remarks:

Exhibit 24.1 Power of Attorney filed with Form 3 on May 12, 2023 and incorporated herein by reference.

### <u>/s/ Bob Myers, Attorney-in-</u> <u>Fact</u> 07/02

07/03/2023

\*\* Signature of Reporting Person Date

Amount or Number

of Shares

Title

Expiration Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

(A) (D)

v

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date

Exercisable

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5